The Patent Finder
NC

Nippon Chemiphar Co., Ltd.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

32 patents currently held

1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Nov 2031. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Nov 2031
Next term end
22
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
P2X4 Receptor Antagonist US 9,382,236
Cited by 23 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Ends Jan 2033 · High confidence
Also notable
Morphinan Derivative US 10,442,802
A family of 6 related applications built on the 2019 grant. Protection runs to 2036.
Ends Mar 2036 · High confidence
Also notable
P2X4 Receptor Antagonist US 10,150,744
Granted 2018. Computed term ends 2034.
Ends Jul 2034 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 6, 2026
    The maintenance fee for Medicament for Treating Cough (US 11,666,582) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
  • 1 fee due Feb 25, 2027
    The maintenance fee for Preventive or Therapeutic Agent for Pain Associated with Herpes Zoster in Acute Phase (US 9,115,123) comes due Feb 25, 2027. Unpaid by Aug 25, 2027, it lapses early.
  • 1 fee due Mar 17, 2027
    The maintenance fee for Drug for Preventing And/Or Treating Dementia (US 10,413,546) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
  • 1 fee due Apr 15, 2027
    The maintenance fee for Morphinan Derivative (US 10,442,802) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
  • 1 fee due May 12, 2027
    The maintenance fee for P2X4 Receptor Antagonist (US 10,472,333) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
  • 1 fee due Sep 5, 2027
    The maintenance fee for Medicament for Treatment of Multiple Sclerosis (US 11,918,589) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
  • 1 fee due Oct 28, 2027
    The maintenance fee for P2X4 Receptor Antagonist (US 10,633,349) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 3 of the patents on this record were granted since Aug 21, 2026
  • 1 term has ended since Aug 21, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 9,115,123Preventive or Therapeutic Agent for Pain Associated with Herpes Zoster in Acute Phase
In force
 · High confidence
In forceHigh confidence
US 9,561,235Preventive or Therapeutic Agent for Pain Associated with Herpes Zoster in Acute Phase
In force
 · High confidence
In forceHigh confidence
US 8,952,030Morphinan Derivative
In force
 · High confidence
In forceHigh confidence
US 9,969,700P2X4 Receptor Antagonist
In force
 · Medium confidence
In forceMedium confidence
US 10,633,349P2X4 Receptor Antagonist
In force
 · Medium confidence
In forceMedium confidence
US 11,434,207P2X4 Receptor Antagonist
In force
 · Low confidence
In forceLow confidence
US 9,382,236P2X4 Receptor Antagonist
In force
 · High confidence
In forceHigh confidence
US 12,116,351P2X4 Receptor Antagonist
In force
 · Medium confidence
In forceMedium confidence
US 10,150,744P2X4 Receptor Antagonist
In force
 · High confidence
In forceHigh confidence
US 10,472,333P2X4 Receptor Antagonist
In force
 · High confidence
In forceHigh confidence
10 of 32 patents shown.
Pro members see all 32.
Pro members: see all 32 patents
Also on record, not counted in the 32: 1 patent in force now held by others · 26 patents ended · 22 applications pending · 35 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited